Newron completes enrollment of Phase II dental pain drug
The study was designed to determine the safety, tolerability and preliminary evidence of preventive analgesic efficacy of orally administered ralfinamide at a dose range of 320/480mg per day,
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.
PNIR will develop and commercialize a therapeutic product for peripheral nerve injury based on Cyberkinetics’s Andara Oscillating Field Stimulator (OFS) neurostimulation technology platform. Each company will have equal